| |
著者: Jerson Laks, Marlos Rocha, Claudia Capitão, Romeu Côrtes Domingues, Giovanna Ladeia, Maurício Lima, Eliasz Engelhardt
雑誌名: Arq Neuropsiquiatr. 2004 Dec;62(4):1092-4. doi: /S0004-282X2004000600030. Epub 2004 Dec 15.
Abstract/Text
Previous reports on the use of olanzapine in Huntington's disease (HD) used doses ranging from 10-30 mg. We report a case of HD with marked delusions and behavioral impairment assessed by the Unified Huntington's Disease Rating Scale at baseline and four months later treated with a low dose of olanzapine. The patient improved in motor, psychiatric and activity of daily living symptoms after four months of treatment. The response to a low dose of olanzapine in HD may be an indicator of efficacy in similar cases. Further randomized controlled trials can properly assess these findings.
PMID 15608976 Arq Neuropsiquiatr. 2004 Dec;62(4):1092-4. doi: /S0004-282X2004000600030. Epub 2004 Dec 15.
|
